ARS Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11682 El Camino Real Ste 300, San Diego,...Phone Number
(858) 771-9307Website
www.ars-pharma.comRevenue
$99 MillionStock Symbol
SPRYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ARS Pharma
ARS Pharm operates as a pharmaceutical company. The Company develops an intranasal epinephrine spray with a unique absorption technology to save patients from allergic reactions of food, medications, and insect bites. Established in 2015, ARS Pharm is headquartered in San Diego, California, United States.Explore more
ARS Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARS Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ARS Pharma launches new products
Check out if ARS Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ARS Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at ARS Pharma
Earning: See what the market has to say on ARS Pharma recently announced quarterly report
Check if ARS Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
ARS Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ARS Pharma had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined ARS Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to ARS Pharma
Compare insights from companies similar to ARS Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ARS Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ARS Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ARS Pharma.
ARS Pharma financials insights
Gather financial insights about ARS Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series C
$20M
2021
Series D
$55M
ARS Pharma Tech Stack
A closer look at the technologies used by ARS Pharma
Most Recent Scoops
Open Position
Earnings
ended Q2 with $143.8 million in cash equivalents and short-term investments, and anticipates reaching cash flow breakeven by the end of 2027.
Accounting, Forecasting, Financial Reporting, Business Finance, Finance
Earnings
ARS Pharma has adjusted its aggregate SG&A and R&D expenses for H2 2026 to a range of $114 million to $126 million, including approximately $14 million to $16 million in stock-based compensation, with total cash-based SG&A and R&D expenses expected in the range of $100 million to $110 million, reflecting a more than 40% reduction in cash-based SG&A from H1 2026.
Earnings, Spending/Investment, Finance
Earnings
ARS Pharma has reported total revenue of $33.7 million for Q2, with total operating expenses of $95.1 million, including $12.8 million in cost of goods sold and $77.6 million in SG&A expenses.
Earnings, Finance
Earnings
Earnings, Finance
ARS Pharma News & Media
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead...ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline
A securities class action alleges ARS Pharmaceuticals overstated its progress toward removing prior authorization barriers with CVS Caremark, the last major PBM standing between neffy and unrestricted commercial access A securities class action alleges ARS Pharmaceuticals overstated its progress toward removing prior authorization barriers with CVS Caremark, the last major PBM standing between neffy and unrestricted commercial accessBronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for ARS Pharmaceuticals Inc. urges investors to seek recovery for alleged securities fraud violations–lead plaintiff deadline of 10/5/2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ARS Pharma
Sign Up For FreeTo access detailed company insights
ARS Pharm operates as a pharmaceutical company. The Company develops an intranasal epinephrine spray with a unique absorption technology to save patients from allergic reactions of food, medications, and insect bites. Established in 2015, ARS Pharm is headquartered in San Diego, California, United States.... Read More
